Literature DB >> 17311420

Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.

Michael R Baldwin1, Joseph T Barbieri.   

Abstract

Botulinum neurotoxins (BoNTs) elicit flaccid paralysis through cleavage of SNARE proteins within peripheral neurons. There are seven serotypes of the BoNTs, termed A-G, which differ in the SNARE protein and/or site that is cleaved. BoNTs are single-chain toxins that comprise an N-terminal zinc metalloprotease domain that is disulfide linked to the C-terminal translocation/receptor binding domain. SV2 and synaptotagmin have been identified as receptors for BoNT serotypes A and B, respectively. Using affinity chromatography, BoNTs A and B were observed to bind synaptic vesicle protein complexes in synaptosome lysates. Tandem LC-MS/MS identified SV2, synaptotagmin I, synaptophysin, vesicle-associated membrane protein 2 (VAMP2), and the vacuolar proton pump as components of the BoNT-receptor complex. Density gradient analysis showed that BoNT serotypes A and B exhibited unique interactions with the synaptic vesicle protein complexes. The association of BoNT serotypes A and B with synaptic vesicle protein complexes implicates a physiological role for protein complexes in synaptic vesicle biology and provides insight into the interactions of BoNT and neuronal receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311420     DOI: 10.1021/bi602396x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

1.  Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.

Authors:  Abby R Kroken; Andrew P-A Karalewitz; Zhuji Fu; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

2.  Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.

Authors:  Million Adane Tegenge; Helge Böhnel; Frank Gessler; Gerd Bicker
Journal:  Cell Mol Neurobiol       Date:  2012-02-29       Impact factor: 5.046

3.  Recombinant holotoxoid vaccine against botulism.

Authors:  Christina L Pier; William H Tepp; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri; Michael R Baldwin
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

4.  Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-03-04       Impact factor: 5.157

5.  Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.

Authors:  Abby R Kroken; Faith C Blum; Madison Zuverink; Joseph T Barbieri
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

6.  Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.

Authors:  Andrew P-A Karalewitz; Zhuji Fu; Michael R Baldwin; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

7.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Authors:  Min Dong; Huisheng Liu; William H Tepp; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

8.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

9.  SV2 mediates entry of tetanus neurotoxin into central neurons.

Authors:  Felix L Yeh; Min Dong; Jun Yao; William H Tepp; Guangyun Lin; Eric A Johnson; Edwin R Chapman
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

10.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.